Persones / Equip Humà

Marçal Pastor-Anglada

Buscador de publicacions

Publicacions

  • Roa H, Gajardo C, Troncoso E, Fuentealba V, Escudero C, Yáñez A, Sobrevia L, Pastor-Anglada M, Quezada C and San Martin R.

    Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats.

    FEBS LETTERS . 583(19): 3192-3198. Nº de cites: 42

    [doi:10.1016/j.febslet.2009.09.003]

  • Molina-Arcas M, Casado FJ and Pastor-Anglada M.

    Nucleoside transporter proteins.

    CURR VASC PHARMACOL . 7(4): 426-434. Nº de cites: 127

    [doi:10.2174/157016109789043892]

  • Vega JL, Puebla C, Vásquez R, Farías M, Alarcón J, Pastor-Anglada M, Krause B, Casanello P and Sobrevia L.

    TGF-beta1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium.

    CARDIOVASC RES . 82(3): 458-467. Nº de cites: 18

    [doi:10.1093/cvr/cvp045]

  • Huber-Ruano I and Pastor-Anglada M.

    Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity.

    CURR DRUG METAB . 10(4): 347-358. Nº de cites: 37

    [doi:10.2174/138920009788499030]

  • Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H and Martinez-Picado J.

    Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.

    J PHARMACOL EXP THER . 329(1): 252-261. Nº de cites: 110

    [doi:10.1124/jpet.108.146225]

  • Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W and Sandvold ML.

    Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.

    SCAND J GASTROENTERO . 44(7): 782-786. Nº de cites: 106

    [doi:10.1080/00365520902745039]

  • Errasti-Murugarren E, Molina-Arcas M, Casado FJ and Pastor-Anglada M.

    A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum.

    FASEB JOURNAL . 23(1): 172-182. Nº de cites: 34

    [doi:10.1096/fj.08-113902]

  • López-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D and Pastor-Anglada M.

    Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.

    HAEMATOLOGICA . 93(12): 1843-1851. Nº de cites: 16

    [doi:10.3324/haematol.13186]

  • Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor-Anglada M, Tse CM and Unadkat JD.

    Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.

    AM J PHYSIOL-GASTR L . 295(3): . Nº de cites: 58

    [doi:10.1152/ajpgi.00542.2007]

  • Perez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M and Mazo A.

    Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.

    BIOCHEMICAL PHARMACOLOGY . 76(3): 322-329. Nº de cites: 42

    [doi:10.1016/j.bcp.2008.05.011]